Abstract
Worldwide about 250 million people are affected by chronic HBV infection (CHB). CHB patients are prone to develop cirrhosis and liver cancer, leading to approximately 1 million deaths each year. Currently, no effective treatment for CHB or liver cancer exists. Antigen specific immunotherapy represents an attractive treatment option. To develop such therapy insight into the presentation of viral and/or tumor antigens in CHB and liver cancer is required. Our efforts to identify target antigens & epitopes for immunotherapy and the subsequent translation of this knowledge towards clinical application will be discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
